Celgene completes $9bn acquisition of Juno Therapeutics

Avenue acquisition sees Cipla build speciality pipeline in US
Credit: Shutterstock.com/ ASDF_MEDIA

Celgene has completed its $9 billion acquisition of Juno Therapeutics advancing the company’s strategy to become a “leader in global cellular immunotherapy”.

Originally announced in January, the acquisition adds novel technology and advanced cellular manufacturing capabilities to Celgene’s broad commercial portfolio and pipeline of therapies addressing serious unmet needs in haematology and oncology.

Celgene also gains full global rights to JCAR017 (lisocabtagene maraleucel; liso-cel), a potentially best-in-class CD-19 targeted CAR T therapy currently in pivotal trials for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).

Celgene expects the addition of JCAR017 and other cellular immunotherapy products in Juno’s pipeline to accelerate revenue diversification with meaningful growth drivers from 2020 and beyond.